4.6 Article

PAX3-FOXO1 and FGFR4 in alveolar rhabdomyosarcoma

Related references

Note: Only part of the references are listed.
Article Biochemistry & Molecular Biology

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells

A. Roidl et al.

ONCOGENE (2010)

Article Pathology

ALK Expression in Rhabdomyosarcomas: Correlation with Histologic Subtype and Fusion Status

Diana A. Corao et al.

PEDIATRIC AND DEVELOPMENTAL PATHOLOGY (2009)

Article Oncology

Clinical significance of CXC chemokine receptor-4 and c-Met in childhood rhabdomyosarcoma

Francesca Diomedi-Camassei et al.

CLINICAL CANCER RESEARCH (2008)

Article Oncology

The pediatric preclinical testing program: Description of models and early testing results

Peter J. Houghton et al.

PEDIATRIC BLOOD & CANCER (2007)

Article Pathology

PAX3-FKHR and PAX7-FKHR fusion genes impact outcome of alveolar rhabdomyosarcoma in children

Bernarda Kazanowska et al.

FETAL AND PEDIATRIC PATHOLOGY (2007)

Article Biochemistry & Molecular Biology

Fgfr4 is required for effective muscle regeneration in vivo -: Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway

P Zhao et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

Article Oncology

Involvement of the FGFr4 Arg388 allele in head and neck squamous cell carcinoma

S Streit et al.

INTERNATIONAL JOURNAL OF CANCER (2004)

Article Biochemistry & Molecular Biology

FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts

PRJ Bois et al.

EMBO JOURNAL (2003)